Abcam, ab229853, Anti-LILRB1 antibody [EPR21007] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal LILRB1 antibody. Carrier free. Suitable for WB, IHC-P and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR21007,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab229853 is the carrier-free version of
ab229186
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
LILRB1 also known as leukocyte immunoglobulin-like receptor subfamily B member 1 or CD85j is a protein expressed mainly on myeloid cells including monocytes and dendritic cells as well as some subsets of lymphocytes. This transmembrane protein is approximately 110-120 kDa in mass and is recognized for its role in immune regulation. LILRB1 interacts with MHC class I molecules on target cells mediating inhibitory signals that prevent immune overactivation. These interactions allow LILRB1 to help maintain self-tolerance and regulate adaptive immune responses.
Biological function summary
LILRB1 functions as an inhibitory receptor that dampens immune system activation by recruiting SHP-1 and SHP-2 phosphatases. As part of a complex with other immune checkpoint molecules LILRB1 modulates the balance between activating and inhibitory signals in immune cells. Its inhibitory signaling prevents excessive inflammation by reducing cytokine production and limiting T cell proliferation.
Pathways
This protein plays a role in immune signaling pathways specifically through interactions with proteins involved in the regulation of immune responses such as KIRs (Killer-cell Immunoglobulin-like Receptors). It participates in pathways that control the inhibitory signals controlling immune activity like the NK cell cytotoxicity pathway and the Fc gamma R-mediated phagocytosis pathway. Through these mechanisms LILRB1 maintains immune equilibrium and preserves tissue integrity during immune responses.
The dysregulation of LILRB1 activity links to autoimmune conditions and infectious disease outcomes. Aberrant expression or function can impact diseases such as rheumatoid arthritis and HIV influencing the progression and severity of these conditions. In rheumatoid arthritis altered LILRB1 signaling may exacerbate inflammation while in the context of HIV it could affect immune cell exhaustion. Furthermore LILRB1 interactions with proteins like ILT2 highlight its potential involvement in modulating immune responses during these diseases.